Other

Chun-ching Shih

Cheng-Hsiu Lin

Chun-Ching Shih

Yueh-Hsiung Kuo

Jin-Bin Wu

Hui-Ya Ho

Jia-Ying Jian

Chang-Syun Yang

The present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane GLUT4 and phospho-Akt in myotubes; and enhancing expression levels of membrane glucose transporter 4 (GLUT4) in skeletal muscle, and phospho-AMPK in both skeletal muscle and liver tissue using dehydroeburicoic acid.

Use of dehydroeburicoic acid fromin the treatment or prevention of diabetes and hyperlipidemia

Provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin K. Also provided is a method of enhancing protein expression ratio of phospho-5' adenosine monophosphate-activated protein kinase (phospho-AMPK) to total AMPK in skeletal muscle or liver of a subject, and a method of reducing blood leptin in a subject. Antcin K exerts prominent antidiabetic and antihyperlipidemic effects through regulation of membrane GLUT4, AMPK, Akt PPAR&#x3b1;, FAS, and PPAR&#x3b3; protein expressions and G6Pase, DGAT2, SREBP-1c, aP2, apoCIII, SREBP2, and PPAR&#x3b1; mRNA expressions.

Method for treatment of hyperglycemia and hyperlipidemia

The present invention provides a method of treating or preventing type 2 diabetes and hyperlipidemia in a subject in need thereof, comprising administrating to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a pharmaceutical composition for treatment or prevention of type 2 diabetes and hyperlipidemia, comprising a compound of formula I and a pharmaceutically acceptable carrier. Through down-regulation of PEPCK, G6Pase, 11&#x3b2;-HSD1, DGAT2, and GPAT, up-regulation of PPAR&#x3b1; and adiponectin, and promotion of membrane GLUT4 expression and phosphorylation of AMPK and Akt, the compound of formula I of the present invention exerts antidiabetic and antihyperlipidemic effects, including reduced weight of visceral fat, decreased blood levels of triglycerides, free fatty acids, glucose, insulin, and leptin as well as decreased hepatic levels of total lipid and triacylglycerol. The compound of formula I also inhibits adipocyte hypertrophy and hepatic ballooning.

Method and composition for treatment or prevention of type 2 diabetes and hyperlipidemia

The present invention provides a method of treating or preventing hyperlipidemia in a subject in need thereof. Such method includes, specifically, administrating to the subject a therapeutically effective amount of a caffeamide derivative. The present invention also provides a pharmaceutical composition containing, primarily, the caffeamide derivative. The method and pharmaceutical composition of the present invention can effectively and significantly lower the high-fat diet-induced body weight gain and absolute visceral fat weight as well as the concentration of triglycerides and free fatty acids in blood, and levels of total lipid and triacylglycerol in liver tissue. In addition, the caffeamide of the present invention also reduces size of adipocyte, hepatocellular ballooning phenomenon, and liver steatosis. Through promotion of phosphorylation of 5' adenosine monophosphate-activated protein kinase (AMPK) in muscle and liver, the caffeamide derivatives of the present invention is suitable for ameliorating or remedying hyperlipidemia.

Method of treating or preventing hyperlipidemia with caffeamide derivatives

The present invention provides a method for treating diabetes, hyperlipidemia or hepatic total lipids by using ergostatrien-3&#x3b2;-ol and its derivatives, as well as a method for decreasing blood glucose and HbA1c levels and reducing blood total cholesterol and triglyceride levels, whereas increasing blood HDL-C levels; and a method for decreasing hepatic total lipid and triacylglycerol levels; and increasing expression levels of membrane glucose transporter 4 (GLUT4) and phospho-Akt in skeletal muscle tissue, and phospho-AMPK in both skeletal muscle and liver tissue using ergostatrien-3&#x3b2;-ol and its derivatives.

Growing community of inventors

Taichung, Taiwan

Cheng-Hsiu Lin